NC318
Phase 2Small molecule
NC318 is one of 7 small molecule programs targeting Advanced Non-Small Cell Lung Cancer. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Advanced Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Lorbrena
PfizerPhase 2
Surufatinib
HHutchison Medipharma Limited
Phase 2
Fabhalta
RegeneronPreclinical
Libtayo
RegeneronPreclinical
Krazati
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
NC318
NNextCure, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced or Metastatic NSCLC1 trial
Advanced or Metastatic Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NC318. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNextCure, Inc.